Search Results
Your search for The ASCO ,The ASCO matches 20588 pages
Showing 11451 - 11500SABCS 2017: Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk
Postmenopausal women who lose weight may have a significantly reduced chance of developing breast cancer, according to data presented by Chlebowski et al at the 2017 San Antonio Breast Cancer Symposium (Abstract GS5-07). “Breast cancer is among the leading types of cancer and...
SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer
Among patients with hormone receptor–positive HER2-negative stage II–III breast cancer without clinical evidence of recurrence, those who had circulating tumor cells (CTCs) detected in blood 5 years after diagnosis had an increased risk for late recurrence of breast cancer, according to ...
FDA Announces Approval, CMS Proposes Coverage of Diagnostic Test for Cancer Biomarkers
On November 30, the U.S. Food and Drug Administration (FDA) approved CDx (F1CDx), a breakthrough-designated, next-generation sequencing–based in vitro diagnostic test that can detect genetic mutations in 324 genes and 2 genomic signatures in any solid tumor type. The Centers for Medicare &...
SABCS 2017: Phase III EMBRACA Trial Meets Primary Endpoint
Patients with advanced HER2-negative breast cancer with germline BRCA mutations had significantly prolonged progression-free survival when treated with the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib, compared with those who received chemotherapy of physician’s choice, according...
FDA Approves First Biosimilar for the Treatment of Certain Breast and Stomach Cancers
On December 1, 2017, the U.S. Food and Drug Administration (FDA) approved trastuzumab-dkst (Ogivri) as a biosimilar to trastuzumab (Herceptin) for the treatment of patients with breast or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors overexpress the HER2 gene. The...
Living a Full Life With Stage IV Non–Small Cell Lung Cancer
The discovery of my non–small cell lung cancer (NCSLC) in 2005 was serendipitous and completely unexpected. A never smoker and physically active my whole life, the only hint something might be amiss was a slight tickle in my throat, which I’m not even sure was related to my cancer diagnosis. In...
Michael A. Caligiuri, MD, Named President of City of Hope National Medical Center
City of Hope announced that it has appointed Michael A. Caligiuri, MD, to a new executive leadership role as President of City of Hope National Medical Center and Physician-in-Chief. Dr. Caligiuri is a health-care visionary, renowned cancer researcher, and President of the American Association for ...
Radiation Oncologist Gives Clear Advice to Patients With Cancer
BOOKMARK Title: Cancer: What You Need to Know: Overcome the 10 Common Mistakes Patients MakeAuthor: Stephen A. Rosenberg, MDPublisher: Stephen Rosenberg, MDYear Published: November 2017Price: $9.99, paperback, 248 pages Stephen A. Rosenberg, MD, is Chief Resident in Radiation Oncology at the...
Old and New Perspectives on the Theory of Cancer
BOOKMARK Title: Tripping Over the Truth: How the Metabolic Theory of Cancer Is Overturning One of Medicine’s Most Entrenched ParadigmsAuthor: Travis Christofferson, MSPublisher: Chelsea Green PublishingPublication Date: February 2017Price: $24.95, hardcover; 288 pages Bringing a book to market is...
Achieving One’s Childhood Dreams While Facing Pancreatic Cancer
BOOMARK Title: The Last LectureAuthor: Randy Pausch with Jeffrey ZaslowPublisher: HyperionDate: April 2008Price: $21.95, hardcover; 206 pages Faced with imminent death, how does one chose to live out the remainder of one’s life? Such is the question at the heart of The Last Lecture, a memoir...
Love Triumphs Amid a Battle With Cancer
BOOKMARK Title: The Red Devil: To Hell With Cancer—and BackAuthor: Katherine Russell RichPublisher: CrownDate Published: October 1999Price: $23.95, hardcover, 256 pages Over the past year or so, there have been several best-selling memoirs of people fighting and ultimately losing their battle with ...
Perlmutter Cancer Center Expands Clinical Leukemia Program
NYU Langone Health has announced that nationally renowned physician and researcher Raoul Tibes, MD, PhD, Associate Professor of Hematology and Medical Oncology at NYU School of Medicine, will lead efforts to expand the clinical and investigative leukemia programs at its Perlmutter Cancer Center....
SITC Spearheads Initiative for Management of Immunotherapy-Related Side Effects
The first consensus recommendations on the recognition and clinical management of immune-related side effects from cancer immunotherapy were recently published in the Journal for ImmunoTherapy of Cancer (JITC).1 The article, “Managing Toxicities Associated With Immune Checkpoint Inhibitors:...
Barbara Savoldo, MD, PhD, Awarded Grant for Immunotherapy Research
University of North Carolina Lineberger Comprehensive Cancer Center researcher Barbara Savoldo, MD, PhD, has been awarded a $600,000, 3-year grant from to support research of an immunotherapy being developed. The grant will help fund clinical research into an investigational chimeric antigen...
Virginia Cancer Specialists and The US Oncology Network Welcome Stephanie Akbari, MD, FACS
Virginia Cancer Specialists, a practice within The US Oncology Network and a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients, has announced that Stephanie Akbari, MD, FACS, has joined the practice. Dr. Akbari, the first dedicated breast...
SABCS 2017: Combined Residual Risk Score Test and Predicting Breast Cancer Risk in Women Who Tested Negative for Hereditary Mutations
Results from a validation study to better define the risk of breast cancer in women of European ancestry who tested negative for a hereditary cancer mutation with a hereditary cancer risk test (myRisk Hereditary Cancer test) were reported earlier this week in a spotlight presentation at the 2017...
Future Directions for CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy burst upon the scene as an innovative approach to the treatment of hematologic malignancies, mainly for patients who have exhausted all other treatment options. Recently two CAR T-cell products were approved by the U.S. Food and Drug Administration...
Seattle Translational Tumor Research Presents Precision-Medicine Grant Winners
Five cross-disciplinary research groups involving scientists from Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, and Seattle Cancer Care Alliance have received $100,000 in awards from Fred Hutchinson Cancer Research Center–based Seattle Translational Tumor...
Born in Chicago, Lymphoma Specialist Sonali M. Smith, MD, Never Left the Windy City
Nationally recognized lymphoma expert Sonali M. Smith, MD, was born and reared in Chicago to a mother who was a pediatrician and allergist, and a father who was an engineer. Her parents were first-generation immigrants from India who placed the value of education second to none. “I became used to...
NCCN Awards Nine Grants for Quality Improvement in Breast Cancer Care
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program in collaboration with Pfizer Global Medical Grants announced they have awarded funding to nine projects that use clinical care pathways to implement quality-improvement initiatives along the continuum of care for...
ASCO Clinical Practice Guideline Update: Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
As reported in the Journal of Clinical Oncology by Arlene A. Forastiere, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and colleagues, ASCO has issued a clinical practice guideline update on the use of larynx-preservation strategies in the treatment of laryngeal cancer. The ...
SABCS 2017: 2 Years of Extended Anastrozole Therapy Proved as Effective as 5 Years in Hormone Receptor–Positive Breast Cancer
Postmenopausal women with hormone receptor–positive breast cancer who took the aromatase inhibitor anastrozole for 2 years after an initial 5 years of adjuvant endocrine therapy received an equal benefit to those who took the drug for 5 additional years. The trial results suggest that a...
SABCS 2017: SOLD Trial Data Support Current Standard 12-Month Adjuvant Trastuzumab for HER2-Positive Breast Cancer
Disease-free survival after 9 weeks of adjuvant trastuzumab (Herceptin) and standard chemotherapy was not comparable to disease-free survival after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current...
Harold J. Burstein, MD, PhD, on HR+ Early Breast Cancer: Update of the SOFT Trial
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses study findings on a comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive breast cancer (Abstract GS4-03).
Melinda Telli, MD, on Triple-Negative Breast Cancer: New Clinical Approaches
Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for better outcomes.
Lisa A. Carey, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial
Lisa A. Carey, MD, of the University of North Carolina, discusses the long-term follow-up of CALGB 40502/NCCTG N063H, a phase III study of weekly paclitaxel compared with weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally...
Immunotherapy Has Indelibly Changed the Treatment Paradigm in Urothelial Carcinoma
Cisplatin-based combination chemotherapy is the preferred first-line therapy for metastatic urothelial cancer and the only treatment shown to improve survival in patients with previously untreated disease for many years. This chemotherapy also has proven to be beneficial in the neoadjuvant and...
Michael Gnant, MD, on Duration of Anastrozole Treatment: Results of the ABCSG-16 Trial
Michael Gnant, MD, of the Medical University of Vienna, discusses phase III study findings on giving an additional 2 vs an additional 5 years of anastrozole after the first 5 years of adjuvant endocrine therapy (Abstract GS3-01).
Immunotherapy Plus Chemotherapy in Non–Small Cell Lung Cancer: Despite the Failure of Ipilimumab, Guarded Optimism Persists
Ipilimumab (Yervoy) is a fully human monoclonal antibody that inhibits cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) and was the first checkpoint inhibitor approved after showing survival benefit in metastatic melanoma.1 Indeed, in the first-line setting for metastatic melanoma, ipilimumab ...
Vered Stearns, MD, and Prudence A. Francis, MD, on ER+ Breast Cancer: Controversies in Adjuvant Treatment
Vered Stearns, MD, of Johns Hopkins University, and Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discuss two key topics in adjuvant treatment: endocrine therapy for premenopausal women with ER+ breast cancer and finding the optimal duration of treatment.
NCCN Introduces New Guidelines for Patients With AIDS-Related Kaposi Sarcoma
The National Comprehensive Cancer Network® (NCCN®) has created a new resource for patients living with human immunodeficiency virus (HIV) who develop acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma. This newly released NCCN Clinical Practice Guidelines in Oncology (NCCN...
Helping Patients With Advanced Disease Transition From Focused to Intrinsic Hope
While hope for a cure after a cancer diagnosis is a feeling both patients and oncologists rightly cling to during treatment, when too much emphasis is placed on this type of “focused” hope, it can make it more difficult for patients to face their mortality. Moreover, such a focus can deny patients ...
National Cancer Institute Awards $12 Million for Breast Cancer Genetics Study
A large study headed by researchers at the Keck School of Medicine of the University of Southern California and two other institutions received $12 million in funding to examine why African American women seem to have more aggressive breast tumors and higher mortality rates from breast cancer than...
ASCO Answers Palliative Care: A Resource for Patients
Do your patients have questions about palliative care/supportive care? Help them better understand their prognosis and goals of treatment, clarify their expectations, and maintain their quality of life with the ASCO Answers Palliative Care booklet. This booklet shows how palliative care is used...
Read the Inaugural ASCO Connection: Cancer Policy Issue
ASCO Connection has released ASCO Connection: Cancer Policy, a supplemental issue that provides the latest information and analysis related to cancer policy news and updates on ASCO’s ongoing advocacy efforts. This inaugural special edition serves as a “year in review” of ASCO’s legislative...
Honor a Loved One With a Gift to Conquer Cancer
This holiday season, fund breakthrough cancer research on behalf of someone you love. Visit CONQUER.ORG/Tribute-Gift to make a tax-deductible gift to Conquer Cancer, ASCO’s affiliate, and send an eCard or mailed notification of your donation. Your support will help fuel the brightest researchers...
CMS Finalizes 340B Cuts, Part B Drugs in Quality Payment Program, 2018 Physician Fee Schedule
The Centers for Medicare & Medicaid Services (CMS) released its final rule on the 2018 Hospital Outpatient Prospective Payment System (PPS). In the rule, CMS finalized a proposal to cut reimbursement for separately paid drugs under the 340B Drug Pricing Program (340B) from average sales price...
Walther Cancer Foundation Endows New ASCO Special Award and Lecture for Palliative and Supportive Care
The Walther Cancer Foundation, Inc., a private foundation based in Indianapolis, Indiana, has endowed a new ASCO award and lecture bearing its name to be presented annually at the Palliative and Supportive Care in Oncology Symposium. This grant represents a new foray for the foundation as it...
Highlights From the Conquer Cancer Foundation’s Third Annual Career Development Retreat
The Conquer Cancer Foundation of ASCO is committed to supporting the research and career development of young researchers through its Grants & Awards Program. In October 2017, Conquer Cancer hosted its third Scientific and Career Development Retreat at ASCO Headquarters in Alexandria,...
New WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Follicular Lymphoma: Is the Road to Cure Paved With Gallium?
The roadside along the path to curing follicular lymphoma is riddled with the debris of failed cytotoxic regimens. For decades, clinical trials unsuccessfully pitted various chemotherapy combinations against each other. It took but a single, noncytotoxic molecule, rituximab (Rituxan), to forever...
Lee S. Schwartzberg, MD, on HR+ Breast Cancer: Treatment Trial Results
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer (Abstract GS4-07).
Mary Pazdur Award for Excellence in Advanced Practice in Oncology Announced
The inaugural Mary Pazdur Award for Excellence in Advanced Practice in Oncology was announced at the 2017 JADPRO Live at APSHO (Advanced Practitioner Society for Hematology and Oncology) conference. Jack Gentile, Chairman of Harborside, which sponsors the JADPRO Live at APSHO conference (and...
Mount Sinai Institutes Join $215 Million Partnership to Increase Patients’ Immunotherapy Success
The Tisch Cancer Institute and the Precision Immunology Institute at Mount Sinai Health System are part of a $215 million public-private Cancer Moonshot research collaboration launched by the National Institutes of Health and 11 leading pharmaceutical companies. The 5-year initiative, called...
Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, on HER2+ Metastatic Breast Cancer: Results From the PANACEA/KEYNOTE 014 Trial
Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).
Louis M. Weiner, MD, Appointed Director of MedStar Georgetown Cancer Institute
MedStar Health, the largest not-for-profit health-care system across Maryland and the Washington, DC, region, has named Louis M. Weiner, MD, as Director of its MedStar Georgetown Cancer Institute. Dr. Weiner will serve in this capacity while also remaining Director of Georgetown Lombardi...
Young Investigators Named Winners of 2017 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 years or younger at the time of nomination for their efforts in advancing cancer research. The...
Concurrent Palliative Care: Recommendations From the ASCO Clinical Practice Guideline
Updated in 2016, the ASCO clinical practice guideline on the integration of palliative care into standard oncology care provides evidence-based recommendations to oncology clinicians, patients, family and friend caregivers, and palliative care specialists about providing high-quality care for...
The 27 NCCN Member Institutions
Fred & Pamela Buffett Cancer Center, Omaha Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland City of Hope Comprehensive Cancer Center, Duarte, California Dana-Farber/Brigham and Women’s Cancer...
International Society of Geriatric Oncology Awards Leaders at 2017 Conference
The International Society of Geriatric Oncology (SIOG) Annual Conference took place November 9–11, 2017, in Warsaw, Poland. Over 350 delegates representing 41 countries attended the meeting, along with more than 60 faculty from 22 countries. Stuart Lichtman, MD, FACP, FASCO, SIOG President, and...
